Nymox Pharmaceutical Corporation news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

NYMX 0.610 +0.010 (1.65%)
price chart
Saving for retirement is a challenge faced by women worldwide
The market's reaction was immediate and dramatic as the price of NYMOX common stock fell 82% to close at $.93 on unprecedented trading volume of 19.6 million shares.
Class Action Lawsuit Filed Against Nymox Pharmaceutical Corporation and Paul ...  GlobeNewswire (press release)
Related articles »  
Here's Why Nymox Share Price Will Fall
Nymox Pharmaceutical Corporation (NYMX) announced Sunday that its experimental drug NX-1207, designed to treat prostate enlargement, did not meet pivotal endpoints in late-stage trials for the drug being run in the US.
Nymox Pharmaceutical Corp. (NYMX) Plunged To A New Low After Study Failed  RTT News
Nymox Drug for Enlarged Prostate Doesn't Meet Targets  Bloomberg
Related articles »  
Nymox Pharmaceutical Corporation: Nymox Reports Third Quarter 2014 ...
Nymox Pharmaceutical Corporation is engaged in the research and development of therapeutics and diagnostics, with an emphasis on products for the unmet needs of the aging population.
Nymox Reports Third Quarter 2014 Financial Results  GlobeNewswire (press release)
Closing Bell News Buzz: Consolidated Edison, Inc. (ED), Exterran Holdings ...  WallStreet Scope
Related articles »  
Amedica Corporation (AMDA), Nymox Pharmaceutical Corporation (NYMX ...
Amedica Corporation (NASDAQ:AMDA) recently stated that it has priced a firm commitment underwritten public offering of 11,441,646 units at a price to the public of $1.14 per unit for gross proceeds of approximately $13.0 million, before deducting ...
Related articles »  
Morning Buzz: Sapient Corp. (SAPE), Nymox Pharmaceutical (NYMX), Twitter ...
Nymox Pharmaceutical (NYMX) stock is getting crushed, down 85%, shaving $4.42 off its stock prices in early trade Monday after the company announced that its two Phase 3 U.S. studies of NX-1207 for the treatment of BPH, NX02-0017 and NX02-0018, ...
Most Active Buzz: SuperCom Ltd. (SPCB), Nymox Pharmaceutical Corporation ...  Market News Call
Trader's Buzzers�Geron (NASDAQ:GERN), Nymox Pharmaceutical (NASDAQ ...  Techsonian (press release)
Related articles »  
Worst Year-To-Date Performers: Nymox Pharmaceutical Corporation (NASDAQ ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has YTD performance of -87.97%. The company has the market capitalization of $ 29.85M.
Stocks in Aggressive Mood: Nymox Pharmaceutical Corporation (NASDAQ ...  Street Newswire (registration)
Related articles »  
Encouraging trial results for Nymox prostate cancer drug candidate (NYMX)
In an analysis of clinical outcomes at eight months in a 146-patient Phase 2 clinical trial evaluating the safety and efficacy of Nymox's (NYMX +3.9%) drug candidate for low grade localized prostate cancer, NX-1207, the proportion of patients who ...
Nymox Pharma (NYMX) Reports Positive Prostate Cancer Trial Results  StreetInsider.com (subscription)
Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results  GlobeNewswire (press release)
Related articles »  
Nymox Reports Second Quarter 2014 Financial Results
HASBROUCK HEIGHTS, N.J., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the second quarter of 2014.
Related articles »  
Worst Year-To-Date Performers: FreeSeas Inc (NASDAQ:FREE), Nymox ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has booked the year to date performance of -86.49% while its market capitalization stands at $ 32.91M.
Investors Waking Up to Nymox Pharmaceuticals
If the 13% rise last week in Nymox Pharmaceuticals' (NASDAQ:NYMX) shares is anything to go by, investors are slowly noticing that the New Jersey-based company is heading into the final furlong of required Phase III tests for its lead product, NX-1207.
Related articles »